Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis

被引:204
作者
Robenshtok, Eyal
Gafter-Gvili, Anat
Goldberg, Elad
Weinberger, Miriam
Yeshurun, Moshe
Leibovici, Leonard
Paul, Mical
机构
[1] Rabin Med Ctr, Dept Med E, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Infect Dis Unit, IL-49100 Petah Tiqwa, Israel
[3] Rabin Med Ctr, Dept Hematol, IL-49100 Petah Tiqwa, Israel
[4] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel
[5] Assaf Harofeh Med Ctr, Infect Dis Unit, IL-70300 Zerifin, Israel
关键词
D O I
10.1200/JCO.2007.12.3851
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the effect of antifungal prophylaxis on all-cause mortality as primary outcome, invasive fungal infections (IFIs), and adverse events. Many studies have evaluated the role of antifungal prophylaxis in cancer patients, with inconsistent conclusions. Methods We performed a systematic review and meta-analysis of randomized, controlled trials comparing systemic antifungals with placebo, no intervention, or other antifungal agents for prophylaxis in cancer patients after chemotherapy. The Cochrane Library, MEDLINE, conference proceedings, and references were searched. Two reviewers independently appraised the quality of trials and extracted data. Results Sixty-four trials met inclusion criteria. Antifungal prophylaxis decreased all-cause mortality significantly at end of follow-up compared with placebo, no treatment, or nonsystemic antifungals (relative risk [RR], 0.84; 95% CI, 0.74 to 0.95). In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, prophylaxis reduced all-cause mortality (RR, 0.62; 95% CI, 0.45 to 0.85), fungal-related mortality, and documented IFI. In acute leukemia patients, there was a significant reduction in fungal-related mortality and documented IFI, whereas the difference in mortality was only borderline significant (RR, 0.88; 95% CI, 0.74 to 1.06). Prophylaxis with itraconazole suspension reduced documented IFI when compared with fluconazole, with no difference in survival, and at the cost of more adverse events. On the basis of two studies, posaconazole prophylaxis reduced all-cause mortality (RR, 0.74; 95% CI, 0.56 to 0.98), fungal-related mortality, and IFI when compared with fluconazole. Conclusion Antifungal prophylaxis decreases all-cause mortality significantly in patients after chemotherapy. Antifungal prophylaxis should be administered to patients undergoing allogeneic HSCT, and should probably be administered to high-risk acute leukemia patients.
引用
收藏
页码:5471 / 5489
页数:19
相关论文
共 154 条
[1]  
AKIYAMA H, 1993, MYCOSES, V36, P373, DOI 10.1111/j.1439-0507.1993.tb00725.x
[2]  
Akiyama H, 1994, Kansenshogaku Zasshi, V68, P327
[3]  
ALEXANDER BD, 2006, TRANSPL INFECT DIS, V20, P8
[4]  
Annaloro C, 1995, HAEMATOLOGICA, V80, P512
[5]  
[Anonymous], 2001, CYTOTHERAPY, V3, P41
[6]  
[Anonymous], COCHRANE HDB SYSTEMA
[7]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[8]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[9]  
BENHAMOU E, 1991, BONE MARROW TRANSPL, V7, P127
[10]   Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections [J].
Benjamin, DK ;
Driscoll, T ;
Seibel, NL ;
Gonzalez, CE ;
Roden, MM ;
Kilaru, R ;
Clark, K ;
Dowell, JA ;
Schranz, J ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :632-638